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Abstract
Acquired platinum resistance is a serious problem in the treatment of ovarian carcinomas. However,
the mechanism of the drug resistance has not been elucidated. Here, we show functional significance
of restoration of BRCA2 protein by secondary BRCA2 mutations in acquired drug resistance of
BRCA2-mutated ovarian carcinoma. Three ovarian cancer cell lines (PEO1, PEO4 and PEO6) were
derived from a BRCA2 mutation (5193C>G (Y1655X)) carrier with ovarian carcinoma with acquired
cisplatin resistance and a secondary BRCA2 mutation (5193C>T (Y1655Y)) that canceled the
inherited mutation. PEO1 was BRCA2-deficient and sensitive to cisplatin and a poly(ADP-ribose)
polymerase inhibitor, AG14361, while PEO4 was resistant. PEO4 and PEO6, derived from ascites
at the time of relapse with cisplatin resistance, had the secondary mutation and were BRCA2-
proficient. In vitro cisplatin/AG14361 selection of PEO1 led to restoration of BRCA2 due to another
secondary BRCA2 mutation. BRCA2 depletion sensitized BRCA2-restored PEO1 clones and PEO4
to cisplatin/AG14361. Thus, restoration of BRCA2 due to secondary BRCA2 mutation is involved
in acquired drug resistance of BRCA2-mutated ovarian carcinoma.
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Introduction
Chemotherapy with platinum compounds, such as cisplatin and carboplatin, is initially
effective for most patients with ovarian carcinomas. However, the majority eventually become
refractory to platinum treatment (1). BRCA2 is a tumor suppressor gene responsible for familial
breast/ovarian cancer. BRCA2 controls homologous recombination by regulating RAD51 (2,
3). BRCA1- and BRCA2- (BRCA1/2) deficient cells are hypersensitive to cisplatin and poly
(ADP-ribose) polymerase (PARP) inhibitors (4-6). Tumors from heterozygous BRCA1/2
mutation carriers usually show loss of heterozygosity at the BRCA1/2 loci and are presumed
to be BRCA1/2 deficient (7-9). Consistently, women with BRCA1/2-mutated ovarian
carcinoma have a better prognosis than those without BRCA1/2 mutation if they receive
platinum-based therapy (10), and PARP inhibitors are becoming a therapeutic option in
BRCA1/2-mutated cancers (6). However, even patients with BRCA1/2-mutated ovarian
carcinoma frequently experience recurrence with platinum resistance.
Acquired resistance to cisplatin in vitro in a BRCA2-mutated pancreatic cancer cell line,
Capan-1, is mediated by secondary mutations in BRCA2 that restore the wild-type BRCA2
reading frame (11,12). Three cases of platinum-resistant recurrent ovarian cancer with
secondary BRCA2 mutation have been reported (11,12), suggesting involvement of secondary
BRCA2 mutation in platinum-resistance of ovarian cancer. However, because of lack of a
human BRCA2-deficient ovarian cancer cell line model, the functional significance of
secondary BRCA2 mutations in ovarian cancer has not been demonstrated. Here, we report the
first human BRCA2-deficient ovarian cancer cell line model and the functional significance
of secondary BRCA2 mutations in acquired drug sensitivity of ovarian cancer cells.
Materials and Methods
Cell lines
Ovarian cancer cell lines (PEO1, 2008, 2008+FANCF, C13*, OAW42, TOV-21G, TOV-112D,
OV-90, PA-1, ES-2, Caov-3, SK-OV-3, SW626, NIH:OVCAR-3, DOV13, RMG-1, A2780,
IGROV-1, OVCAR-5, OVCAR-8, A1847, OAW28, COLO720E, 59M) (13) and PEO6 (14)
were described previously. PEO1 and PEO4 (15) were gifts from Dr. S. Williams (Fox Chase
Cancer Center). Cell lines were grown in DMEM with 10% fetal calf serum in a humidified
5% CO2-containing atmosphere at 37°C. Gamma irradiation was delivered using a JL Shepherd
Mark I Cesium Irradiator (JL Shepherd & associates, San Fernando, CA). PEO1 cells were
selected in cisplatin (4μM) (Sigma, St. Louis, MO) or a PARP inhibitor (AG14361 (4μM), a
gift of Pfizer) -containing medium for 4 weeks. Drug-resistant colonies were picked and
expanded in normal medium. Initially, 14 cisplatin-selected clones were picked, but three of
them (C4-3, C4-8, and C4-9) were omitted, because C4-8 and C4-9 did not grow and C4-3
turned out to be a mixed population. Therefore, 11 cisplatin-selected clones were analyzed.
Initially, 12 AG14361-selected clones were picked, but nine of them were omitted, because
they did not grow. Therefore, three AG14361-selected clones were analyzed.
Western blot analysis and immunofluorescence microscopy
BRCA2 western blotting using anti-BRCA2 Ab-1 (OP95, EMD Biosciences) and Ab-2
(PC146, EMD Biosciences) and immunostaining for RAD51 were done as described (11).
BRCA2 sequencing
Extraction of genomic DNA and RNA, reverse transcription, PCR and sequencing of
BRCA2 were done as described (11). All nucleotide numbers refer to the cDNA human
sequence of BRCA2 (accession no. U43746; version U43746.1 GI: 1161383) (GenBank).
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Drug sensitivity assays
Cisplatin/AG14361 sensitivity of cells was determined by crystal violet assay as described
(11).
siRNA transfection
Expression of BRCA2 was knocked down by transient transfection of siRNA directed against
BRCA2 (#1 (5’-AACAACAATTACGAACCAAAC-3’), #2 (5'-
CAGGACACAATTACAACTAAA-3')) and negative control (5’-
AATTCTCCGAACGTGTCACGT-3’) as described (11). Final concentration of siRNA was
50nM. Two or three days after transfection, cells were used for drug sensitivity assays, western
blotting and immunofluorescence experiments.
In vitro homologous recombination assay
V-C8-DR-GFP cells were transfected with either pcDNA3.1 vector, pcBAsce1 vector
containing the I-SceI restriction endonuclease gene, or pcBAsce1 plus various FLAG tagged
BRCA2-pcDNA3.1 constructs. After 72 h, cells were harvested and the number of green
fluorescent protein (GFP)–expressing cells was assessed by flow cytometry. In parallel, we
determined transfection/expression efficiency for BRCA2 by fluorescently labeling cells from
these transfection experiments with an anti-FLAG antibody and counting the number of FLAG-
BRCA2–expressing cells per 1,000 cells using a fluorescence microscope. The ratio of GFP-
expressing cells induced by wild-type or mutant BRCA2 compared with vector control in the
homologous recombination assay was then plotted after adjustment for transfection efficiency
(11).
Clinical specimens
Tissue samples from the BRCA2-mutated ovarian cancer patient from whom the ovarian cancer
cell lines, PEO1, PEO4 and PEO6, were derived were obtained from the University of
Edinburgh. The study was approved by Institutional Review Boards of Fred Hutchinson Cancer
Research Center.
Results and Discussion
We tested 25 ovarian cancer cell lines for expression of BRCA2 protein and found that BRCA2
protein was undetectable in PEO1 (Fig 1A). PEO1 was derived from the ascites of a patient
with poorly differentiated ovarian serous adenocarcinoma that was still clinically responsive
to cisplatin at the first relapse (14,15). The clinical course of this patient is summarized in Fig
1B. Remarkably, in two ovarian cancer cell lines (PEO4 and PEO6) derived from the same
patient obtained when her carcinoma had acquired clinical cisplatin resistance, BRCA2 protein
was detectable (Fig 1A). PEO1 was sensitive to cisplatin and a PARP inhibitor (AG14361),
while PEO4 was resistant (Figs 1C and 2D), consistent with the BRCA2 protein expression
status.
The patient turned out to be a heterozygous carrier of BRCA2.5193C>G (Y1655X) nonsense
mutation (Fig 1D). Consistently, PEO1 had the hemizygous nonsense mutation (5193C>G).
PEO1 is the first and only human BRCA2-deficient ovarian cancer cell line described, to the
best of our knowledge.
Interestingly, PEO4 and PEO6 had a silent mutation (5193C>T, Y1655Y) instead (Fig 1D). In
neoplastic cells in the ascites from which PEO4 and PEO6 were derived, at the relapse with
clinical cisplatin resistance, 5193C>T was also detected. Thus, the secondary mutation
(5193C>T) which canceled the inherited nonsense mutation (5193C>G) occurred in vivo.
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Next, we selected PEO1 cells in cisplatin-containing medium (4μM) for four weeks in vitro
and obtained 11 clones out of two million cells. Eight of them restored BRCA2 protein (Fig
2A) and had a secondary BRCA2 mutation (5192A>T) (Figs 2B and 2C). This mutation is a
single base pair substitution that changed the stop codon into an amino acid coding triplet
leading to the restoration of the open reading frame (5192A>T; 5193C>G, Y1655L).
The eight BRCA2-restored PEO1 clones and PEO4 were cisplatin- and AG14361-resistant
compared to parental PEO1 (Fig 2D), consistent with functionality of the restored BRCA2
proteins. Two of the three clones without BRCA2 restoration (C4-4, and C4-11) were cisplatin
resistant, while the other clone (C4-13) was only slightly resistant. One of the cisplatin-resistant
clones without restored BRCA2 (C4-4) was still sensitive to AG14361, consistent with the
lack of BRCA2. Two cisplatin-resistant clones without restored BRCA2 (C4-11 and C4-13)
showed intermediate sensitivity to AG14361, suggesting the existence of alternative
mechanisms for the drug resistance.
Next, we analyzed the homologous recombination-based DNA double-strand-break repair
function of the novel BRCA2 proteins using an I-SceI-dependent DR-GFP reporter assay in
BRCA2-deficient V-C8 cells (16,17) (Fig 3A and Supplemental Fig S1). In this assay, GFP
expression correlates with the occurrence of homologous recombination. Transfection of a
wild-type BRCA2 construct or constructs with the secondary BRCA2 mutations ((5192A>T;
5193C>G, Y1655L) or (5193C>T, Y1655Y)) resulted in seven to eight-fold more GFP-
positive cells compared to control, whereas transfection of the 5193C>T (Y1655X) mutant
construct resulted in impaired induction of GFP-positive cells. These results indicate that the
secondary-mutated BRCA2 proteins efficiently promote homologous recombination.
Functional BRCA2 is required for ionizing radiation-induced RAD51 foci formation (4).
Consistently, in parental PEO1 cells and the three BRCA2-non-restored PEO1 clones, ionizing
radiation-induced RAD51 foci formation was severely impaired (Fig 3B). In contrast, it was
restored in the eight BRCA2-restored PEO1 clones and in PEO4, again suggesting that the
secondary-mutated BRCA2 proteins are functional.
Next, we depleted BRCA2 in two BRCA2-restored clones (C4-2 and C4-5) and PEO4 by
siRNA transfection (Fig 4). The BRCA2-depleted cells became sensitive to cisplatin/
AG14361, indicating that the restored BRCA2 proteins are critical for the acquired cisplatin/
AG14361 resistance. We confirmed this result using another BRCA2 siRNA (Supplemental
Fig S2). In contrast, BRCA2 siRNA had no effect on drug sensitivity of a BRCA2-non-restored
clone C4-11 and parental PEO1 (Fig 4).
We also selected PEO1 cells in AG14361-containing medium (4μM) for four weeks and
obtained three clones out of one million cells. These clones restored BRCA2 protein, harbored
the same secondary mutation (5192A>T), showed restored RAD51 foci formation, and were
resistant to both cisplatin and AG14361 (Supplemental Fig S3A-D). Depletion of BRCA2
sensitized these clones to cisplatin and AG14361 (Supplemental Fig S3E-F, S4), indicating
that restored BRCA2 was critical for the drug resistance.
These findings provide compelling evidence that restoration of functional BRCA2 protein by
secondary BRCA2 mutation has a critical role in acquired platinum/PARP inhibitor resistance
of BRCA2-mutated ovarian carcinomas. This concept has two important clinical implications.
First, it suggests the importance of testing BRCA2 mutation status in recurrent ovarian
carcinomas in BRCA2 mutation carriers to predict their response to platinum and PARP
inhibitors. Second, it provides a theoretical basis for a strategy to overcome platinum/PARP
inhibitor resistance. If the mechanism of resistance is restoration of BRCA2, inhibiting BRCA2
function is a logical way to re-sensitize the tumor to the drugs.
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We may be able to apply the concept to other genes regulating DNA repair, such as BRCA1
and ATM. Indeed, secondary mutations of BRCA1 occur in BRCA1-mutated ovarian cancer
with platinum resistance (18). Whether we can apply the concept to sporadic ovarian
carcinomas with reduced BRCA1 or BRCA2 expression (19) is also an important issue to be
addressed in the future.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. PEO1 is a BRCA2-deficient ovarian cancer cell line
(Full-length blots are presented in Supplemental Fig. S5A-B)
A. BRCA2 western blotting of 25 ovarian cancer cell lines.
B. Clinical course of the patient with an ovarian cancer from which PEO1, PEO4 and PEO6
were derived (reconstituted using published information (14,15)). Timings of collection of
samples used to generate the cell lines were also shown.
C. Cisplatin sensitivity assessed by crystal violet assay. 2008 and 2008+FANCF are a cisplatin-
sensitive and a cisplatin-resistant control, respectively (13).
D. DNA sequences of BRCA2. In PEO1, a nonsense mutation (5193C>G, Y1655X) was
observed. In PEO4 and PEO6, a silent mutation on the same base (5193C>T, Y1655Y) was
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observed. In the non-tumor cells of the patient, a heterozygous mutation (5193C>G) was
detected. In tumor cells from the ascites both at the second relapse and at the terminal phase,
a secondary BRCA2 mutation (5193C>T) was detected.
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Figure 2. Restoration of BRCA2 protein by secondary BRCA2 mutation in cisplatin-selected PEO1
clones
(Full-length blots are presented in Supplemental Fig. S5C)
A. BRCA2 western blotting of the 11 clones of PEO1 generated by selecting the cells in the
presence of cisplatin. Eight PEO1 clones indicated with a single asterisk restored BRCA2
protein expression. A double asterisk indicates a band presumed to be non-specific.
B. DNA sequence of BRCA2 in C4-1. In addition to the original mutation (5193C>G), a
secondary mutation (5192A>T) was observed. The same mutation was observed in C4-2, C4-5,
C4-6, C4-7, C4-10, C4-12 and C4-14 (data not shown). The mutation was confirmed in cDNAs
(data not shown).
C. Schematic presentation of BRCA2 proteins encoded by transcripts in PEO1 clones, PEO4
and PEO6. The secondary genetic changes (shown as white arrow heads) cancel the nonsense
mutation caused by the original mutation (5193C>G, black arrow heads), and the encoded
BRCA2 proteins have intact C-terminal regions containing a single strand DNA (ssDNA)
binding domain and nuclear localization signals (NLS). The regions that the BRCA2 antibodies
(Ab-1 and Ab-2) recognize are depicted.
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D. Cisplatin/AG14361 sensitivity of the PEO1 clones. Mean values of at least three
independent experiments ± SEM are shown. All of the cisplatin-selected PEO1 clones and
PEO4 are cisplatin resistant compared to parental PEO1 (p<0.05, LD50 data were compared
by unpaired t test). All of the cisplatin-selected PEO1 clones (except for C4-4) and PEO4 were
AG14361 resistant compared to parental PEO1 (p<0.05, LD50 data were compared by unpaired
t test).
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Figure 3. The restored BRCA2 proteins with secondary BRCA2 mutations are functional
A. Quantitation of homologous recombination induced by I-SceI in VC8-DR-GFP cells
transiently transfected with wild-type and mutant forms of FLAG-tagged human BRCA2
cDNA. The proportion of GFP-positive cells for each construct relative to vector control is
shown (mean ± SEM). Asterisks (*) indicate significant difference with wild-type BRCA2
cDNA-transfected cells (p<0.05, unpaired t test).
B. Ionizing radiation (IR)-induced RAD51 foci formation is restored in the BRCA2-restored
PEO1 clones. Indicated cells were irradiated (15 Gy) and fixed 12 hours after IR. Cells were
immunostained with RAD51 antibody. Representative pictures of immunostained cells after
IR are shown, together with quantification of the cells with at least five RAD51 foci before (−,
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white bars) and 12 hours after IR (+, grey bars). Mean values of at least three independent
experiments ± SEM are shown. Asterisks (*) indicate significant difference with irradiated
parental PEO1 cells (p<0.05, unpaired t test). Scale bar = 20 μm. Counterstains for the DNA-
specific dye 4’, 6-diamidino-2-phenylindole dihydrochloride (DAPI) are also shown.
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Figure 4. BRCA2 restoration is critical for acquired drug resistance
(Full-length blots are presented in Supplemental Fig. S5D)
A. BRCA2 western blotting of PEO1, PEO4, C4-2, C4-5, and C4-11 cells treated with indicated
siRNA. BRCA2 siRNA #1 was used in this experiment.
B. Cisplatin sensitivity assessed by crystal violet assay. PEO4, C4-2 and C4-5 were resistant
to cisplatin. BRCA2 siRNA (#1)- treated PEO4, C4-2 and C4-5 cells are cisplatin-sensitive
compared to control siRNA-treated cells. (p<0.05, LD50 data were compared by unpaired t
test). BRCA2 siRNA had no effect on cisplatin sensitivity of PEO1 and C4-11 cells. (mean ±
SEM, n=3)
C. AG14361 sensitivity assessed by crystal violet assay. PEO4, C4-2 and C4-5 were resistant
to AG14361. BRCA2 siRNA (#1)-treated PEO4, and C4-2 cells were AG14361-sensitive
compared to control siRNA-treated cells (p<0.05, LD50 data were compared by unpaired t test).
BRCA2 siRNA (#1)-treated C4-5 cells tended to be AG14361-sensitive compared to control
siRNA-treated cells, but the difference is not statistically significant (p=0.067). BRCA2 siRNA
(#1) had no effect on AG14361 sensitivity of PEO1 and C4-11 cells. (mean ± SEM, n=3)
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